Brain Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The market size of Brain Cancer is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Genentech, Merck, Azurity Pharmaceuticals, Sevier, Kazia Therapeutics, Chimerix, Aivita Bio-medical, Medicenna Therapeutics

[Nevada, United States] - DelveInsight's "Brain Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Brain Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Brain Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/brain-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Brain Cancer Market Report:
The Brain Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In August, 2024: Reveal Pharmaceuticals Inc. announced that the goal of their study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging.
In August, 2024: Shanghai Pharmaceuticals Holding Co., Ltd announced that their study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
In July, 2024: GT Medical Technologies, Inc. announced that their trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
In May, 2024: Bristol-Myers Squibb announced that the purpose of their study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation therapy.
According to DelveInsight analysis, the United States contributed to the largest incident population in 2022, accounting around 40% of the total incident cases of glioma, which is expected to increase during the forecast period.
In the 7MM, the maximum number of cases were found for Grade IV glioma, accounting for nearly33,000 cases in 2022,which is followed by Grade II and Grade III glioma.
Among the EU4 and the UK, Germany accounted for the highest number of GBM cases, followed by France, whereasItalyaccounted for the lowest cases in 2022.
Key Brain Cancer Companies are as follows: Genentech, Merck, Azurity Pharmaceuticals, Sevier, Kazia Therapeutics, Chimerix, Aivita Bio-medical, Medicenna Therapeutics
Key Brain Cancer Therapies are as follow: AVASTIN, TEMODAR/TEMODAL, GLIADEL Wafer, Vorasidenib, Paxalisib, ONC201, AV GBM 1, MDNA55.
Launching multiple stage Brain Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Brain Cancer market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Brain Cancer Overview:
A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases thathave in common the abnormal development of mass lesions in the brain, spinal cord or its coverings. A brain tumor can beclassified into two main groups, i.e., primary and metastatic.

Brain Cancer Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Brain Cancer Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Brain Cancer companies working in the treatment market, visit Brain Cancer Clinical Trials

Brain Cancer Therapies and Key Companies:
AVASTIN (bevacizumab): Genentech
TEMODAR/TEMODAL: Merck
GLIADEL Wafer: Azurity Pharmaceuticals
Vorasidenib: Servier
Paxalisib: Kazia Therapeutics
ONC201: Chimerix
AV GBM 1: Aivita Bio-medical
MDNA55: Medicenna Therapeutics

Brain Cancer Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Brain Cancer.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Brain Cancer Epidemiology Segmentation:
The Brain Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Brain Cancer Total Prevalence
Brain Cancer Prevalent Cases by severity
Brain Cancer Gender-specific Prevalence
Brain Cancer Diagnosed Cases of Episodic and Chronic

Brain Cancer Market Drivers:
Rising Incidence of Brain Cancer
Advancements in Diagnostic Technologies
Development of Targeted Therapies
Increased Funding and Research Initiatives

Brain Cancer Market Barriers:
Limited Treatment Options for Aggressive Tumors
Complexity of Drug Delivery to the Brain
Adverse Side Effects of Treatment
Low Survival Rates and Poor Prognosis

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Brain Cancer Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Brain Cancer Companies: Genentech, Merck, Azurity Pharmaceuticals, Sevier, Kazia Therapeutics, Chimerix, Aivita Bio-medical, Medicenna Therapeutics
Key Brain Cancer Therapies: AVASTIN, TEMODAR/TEMODAL, GLIADEL Wafer, Vorasidenib, Paxalisib, ONC201, AV GBM 1, MDNA55.
Brain Cancer Therapeutic Assessment: Current marketed and emerging therapies
Brain Cancer Market Dynamics: Brain Cancer Market drivers and Brain Cancer barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Brain Cancer Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Brain Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Executive Summary
4 Brain Cancer Market Overview at a Glance
5 Key Events
6 Epidemiology and Market Forecast Methodology
7 Disease Background and Overview
8 Treatment
9 Treatment Algorithm
10 Epidemiology and Patient Population
11 Patient Journey
12 Marketed Drugs
13 Emerging Therapies
14 Brain Cancer: Seven Major Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Reimbursement and Market Access
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.